Cinclus Pharma Holding, a clinical-stage biopharmaceutical company focused on developing novel therapies for the treatment of gastric acid-related diseases, has announced an agreement with Zentiva, a European pharmaceutical company, for the commercialisation and manufacturing of its lead asset, linaprazan glurate, in Europe.
